Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Gilead Approves 2-for-1 Split as Shares Close to Record

Dec. 10 (Bloomberg) -- Gilead Sciences Inc.’s board scheduled a 2-for-1 stock split as optimism about the company’s experimental hepatitis C drug pushed shares to record highs.

Stockholders on Jan. 7, will receive an additional share, Gilead said today in a statement. The split will increase the number of outstanding common shares to 1.5 billion, the Foster City, California-based company said. After such an action, a company’s stock usually trades at half as much per share as before the division.

Gilead, the world’s largest maker of HIV medicines, rose less than 1 percent to $74.25 at the close in New York before the split was announced. The company’s shares closed at $76.12 on Nov. 23, the highest level since Gilead first offered stock in 1992, as its experimental drugs to treat hepatitis C have shown to be effective and safe in clinical trials.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.